Sunshine Biopharma SBFM

$2.93 -0.40 (-12.01%)

Valuation

Market cap
631,000
Revenue TTM
$36,310,000
Net income TTM
$-5,980,000
PE ratio
0.00
Forward PE
—
Profit margin
-16.47%
Debt to equity
0.00

Trading

Volume
113,900
Avg volume
373,407
Day's range
$2.65 – $3.21
Shares out
216,000
Stochastic %K
15%
Beta
1.20
Analysts
Sell
Price target
$56.00

Price

Company profile

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, a...

Show more

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
954 330 0684
Website
https://sunshinebiopharma.com
Address
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, United States

Latest news

No headlines yet.